Leeward Investments LLC MA Sells 5,921 Shares of Labcorp Holdings Inc. $LH

Leeward Investments LLC MA cut its holdings in shares of Labcorp Holdings Inc. (NYSE:LH) by 14.3% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 35,533 shares of the medical research company’s stock after selling 5,921 shares during the quarter. Leeward Investments LLC MA’s holdings in Labcorp were worth $10,948,000 at the end of the most recent reporting period.

Several other large investors also recently bought and sold shares of LH. Signaturefd LLC lifted its stake in Labcorp by 4.9% in the 3rd quarter. Signaturefd LLC now owns 687 shares of the medical research company’s stock worth $212,000 after purchasing an additional 32 shares in the last quarter. CoreCap Advisors LLC boosted its holdings in shares of Labcorp by 13.8% during the 3rd quarter. CoreCap Advisors LLC now owns 289 shares of the medical research company’s stock worth $89,000 after purchasing an additional 35 shares during the last quarter. Krilogy Financial LLC boosted its holdings in shares of Labcorp by 2.4% during the 3rd quarter. Krilogy Financial LLC now owns 1,590 shares of the medical research company’s stock worth $502,000 after purchasing an additional 37 shares during the last quarter. V Square Quantitative Management LLC boosted its holdings in shares of Labcorp by 1.7% during the 1st quarter. V Square Quantitative Management LLC now owns 2,418 shares of the medical research company’s stock worth $645,000 after purchasing an additional 40 shares during the last quarter. Finally, Meeder Advisory Services Inc. grew its position in shares of Labcorp by 4.5% in the first quarter. Meeder Advisory Services Inc. now owns 1,021 shares of the medical research company’s stock valued at $272,000 after purchasing an additional 44 shares in the last quarter. Hedge funds and other institutional investors own 95.94% of the company’s stock.

Labcorp Price Performance

Labcorp stock opened at $329.10 on Monday. Labcorp Holdings Inc. has a 12-month low of $244.52 and a 12-month high of $341.80. The stock has a market cap of $26.69 billion, a P/E ratio of 27.22, a PEG ratio of 1.88 and a beta of 0.87. The company has a 50-day moving average price of $320.94 and a 200 day moving average price of $291.11. The company has a current ratio of 1.80, a quick ratio of 1.53 and a debt-to-equity ratio of 0.69.

Labcorp (NYSE:LH) last issued its earnings results on Thursday, July 30th. The medical research company reported $4.99 EPS for the quarter, topping analysts’ consensus estimates of $4.78 by $0.21. The company had revenue of $3.73 billion for the quarter, compared to the consensus estimate of $3.71 billion. Labcorp had a net margin of 6.99% and a return on equity of 16.74%. Labcorp’s quarterly revenue was up 5.8% compared to the same quarter last year. During the same period in the previous year, the firm earned $4.35 earnings per share. Labcorp has set its FY 2026 guidance at 18.100-18.550 EPS. Sell-side analysts anticipate that Labcorp Holdings Inc. will post 18.32 earnings per share for the current year.

Labcorp Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Friday, December 11th. Stockholders of record on Tuesday, November 24th will be issued a dividend of $0.72 per share. The ex-dividend date is Tuesday, November 24th. This represents a $2.88 dividend on an annualized basis and a dividend yield of 0.9%. Labcorp’s dividend payout ratio (DPR) is currently 23.82%.

Wall Street Analyst Weigh In

LH has been the subject of several recent research reports. UBS Group increased their price target on Labcorp from $361.00 to $380.00 and gave the company a “buy” rating in a report on Friday, September 11th. Truist Financial lifted their price objective on Labcorp from $350.00 to $365.00 and gave the stock a “buy” rating in a research report on Monday, September 21st. Bank of America boosted their price objective on Labcorp from $300.00 to $320.00 and gave the stock a “buy” rating in a research note on Monday, July 13th. Robert W. Baird set a $352.00 target price on Labcorp in a report on Friday, July 31st. Finally, Weiss Ratings upgraded Labcorp from a “buy (b+)” rating to a “buy (a-)” rating in a report on Wednesday. One research analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating and three have issued a Hold rating to the company. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $337.73.

Insider Transactions at Labcorp

In related news, CEO Adam H. Schechter sold 4,669 shares of the company’s stock in a transaction that occurred on Tuesday, August 11th. The stock was sold at an average price of $320.37, for a total value of $1,495,807.53. Following the transaction, the chief executive officer directly owned 102,565 shares in the company, valued at approximately $32,858,749.05. This represents a 4.35% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Amy B. Summy sold 924 shares of the company’s stock in a transaction that occurred on Tuesday, August 4th. The shares were sold at an average price of $306.74, for a total value of $283,427.76. Following the completion of the transaction, the executive vice president owned 6,956 shares in the company, valued at $2,133,683.44. This represents a 11.73% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 8,593 shares of company stock worth $2,733,295 in the last 90 days. Insiders own 0.84% of the company’s stock.

Labcorp Company Profile

Labcorp (NYSE: LH), formally Laboratory Corporation of America Holdings, is a global life sciences and healthcare company headquartered in Burlington, North Carolina. The company provides laboratory testing and diagnostic services to physicians, hospitals, health systems, employers, insurers and consumers.

Through its diagnostics operations, Labcorp offers routine and specialty testing, oncology diagnostics, women’s health testing, genetic testing, pathology services and other laboratory services.